Global Endocarditis Drug Market By Type (Acute Endocarditis and Subacute Endocarditis), Therapy Type (Antibiotic Therapy and Recombinant Enzyme Therapy), Treatment (Medication, Surgery), Drug Class Type (Carbapenems, Aminoglycosides, Cephalosporins, Penicillinase Resistant Penicillins), Route of Administration (Oral and Injectable), Diagnosis Type (Blood Cultures, Echocardiography, Serological Tests), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends & Forecast to 2026
Few of the major competitors currently working in the global endocarditis drug market are Abbott, Merck & Co., Inc, Allergan, ContraFect Corporation, Novartis AG, Cumberland Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd, Basilea Pharmaceutica Ltd., NuvOx Pharma, CytoSorbents Corporation, Edwards Lifesciences Corporation, Danaher, bioMérieux SA, Quidel Corporation, Aesculap, Bayer AG, Sun Pharmaceutical Industries Ltd, Cipla Inc, Boston Pharmaceuticals, dhpharm.co.kr, INTELGENX CORP. and many others.
Get a Sample Report Now @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-endocarditis-drug-market
Market Analysis: Global Endocarditis Drug Market
The global endocarditis drug market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. Growing incidence of endocarditis’s population and the development of advanced therapies and treatment are the key factors for market growth.
Market Definition:
Endocarditis, also known as bacterial infective endocarditis is defined as bacterial infection in the endocardium, inner lining of the heart muscle. If untreated the bacterial infections may spread to heart valves and results in heart failure. The person with endocarditis may experience fever, pain in muscle and joints, shortness of breath and poor appetite.
According to the article published in the journal of the American college of cardiology, it is estimated, that the incidence of endocarditis is raising in the U.S with 40,000 to 50,000 new cases every year. The growing rate of endocarditis worldwide and advances in antibiotics and treatment are the key players for growth of market.
Market Drivers
- Increase in prevalence rate of endocarditis disorders worldwide
- Rising awareness about endocarditis therapy along with the technological advancement is driving the market growth
- Increase in the rate of research and development initiatives is boosting the market growth
- Ongoing clinical trials carried out by many pharmaceuticals companies is also driving the growth of the market
Market Restraints
- Effective treatment is either unavailable or unaffordable
- Patent expiry of major drugs and introduction of generic drugs of branded version is expected to restrict the market growth
- Inadequate knowledge about endocarditis in some developing countries
Download Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-endocarditis-drug-market
Segmentation: Global Endocarditis Drug Market
By Type
- Acute endocarditis
- Subacute endocarditis
By Therapy Type
- Antibiotic therapy
- Recombinant enzyme Therapy
By Treatment
- Medication
- Surgery
By Drug Class Type
- Carbapenems
- Cilastatin
- Aminoglycosides
- Streptomycin
- Tobramycin
- Garamycin
- Cephalosporins
- Cefazolin
- Ceftazidime
- Penicillinase resistant penicillins
- Oxacillin
By Route of administration
- Oral
- Injectable
By Diagnosis Type
- Blood cultures
- Echocardiography
- Serological tests
By End Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
By Geography
- North America
- South America
- Europe
- Asia-Pacific
- Middle East & Africa
Key Developments in the Market:
- In April 2019, ContraFect Corporation has reported in their press release that Exebacase, a recombinantly -produced lysin demonstrated the primary efficacy endpoints of Phase II trial ongoing in patients with endocarditis. If approved, it will expand the company’s portfolio in the therapeutic area of cardiology.
- In August 2016, NuvOx Pharma received a grant from the National Institute of Child Health and Human development (NICHD) of USD 24.31 million for developing novel therapy for the treatment endocarditis. This grant helps the company in expanding its business segment in field of cardiology therapeutics.
Competitive Analysis:
Global endocarditis drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of endocarditis drug market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Reasons to Purchase this Report
- Current and future of global endocarditis drug market outlook in the developed and emerging markets
- The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
- Regions/Countries that are expected to witness the fastest growth rates during the forecast period
- The latest developments, market shares, and strategies that are employed by the major market players
Order a Copy of This Research Report @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-endocarditis-drug-market